The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: A conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype

Modern Pathology

Volumn 27, Issue 5, 2014, Pages 690-700

  Kadota, Kyuichi ^a,b   Yeh, Yi Chen ^a   Sima, Camelia S ^a   Rusch, Valerie W ^a   Moreira, Andre L ^a   Adusumilli, Prasad S ^a   Travis, William D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

cribriform; histologic subtype; lung adenocarcinoma; recurrence

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; THYROID TRANSCRIPTION FACTOR 1;

ACINAR CELL CARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATIONAL STUDY; CRIBRIFORM PREDOMINANT TUMOR; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SOLID TUMOR; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR RECURRENCE; ADENOCARCINOMA; CANCER STAGING; CLASSIFICATION; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84899935475     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.188     Document Type: Article

References (43)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics,2011. CA Cancer J Clin 2011;61:212-236.
2. Jemal A, Bray F, Center MM, et al. Global cancerstatistics. CA Cancer J Clin 2011;61:69-90.
3. Devesa SS, Bray F, Vizcaino AP, et al. Internationallung cancer trends by histologic type: male:femaledifferences diminishing and adenocarcinoma ratesrising. Int J Cancer 2005;117:294-299.
4. Barletta JA, Yeap BY, Chirieac LR. Prognostic significanceof grading in lung adenocarcinoma. Cancer2010;116:659-669.
5. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma:modification of the 2004 WHO mixed subtype to includethe major histologic subtype suggests correlationsbetween papillary and micropapillary adenocarcinomasubtypes, EGFR mutations and gene expression analysis.Am J Surg Pathol 2008;32:810-827.
6. Sica G, Yoshizawa A, Sima CS, et al. A grading systemof lung adenocarcinomas based on histologic pattern ispredictive of disease recurrence in stage I tumors. Am JSurg Pathol 2010;34:1155-1162.
7. Maeshima AM, Tochigi N, Yoshida A, et al. Histologicalscoring for small lung adenocarcinomas 2 cm orless in diameter: a reliable prognostic indicator.J Thorac Oncol 2010;5:333-339.
8. Noguchi M, Morikawa A, Kawasaki M, et al. Smalladenocarcinoma of the lung. Histologic characteristicsand prognosis. Cancer 1995;75:2844-2852.
9. Travis WD, Brambilla E, Noguchi M, et al. InternationalAssociation for the Study of Lung Cancer/AmericanThoracic Society/European Respiratory Society internationalmultidisciplinary classification of lung adenocarcinoma.J Thorac Oncol 2011;6:244-285.
10. Yoshizawa A, Motoi N, Riely GJ, et al. Impact ofproposed IASLC/ATS/ERS classification of lung adenocarcinoma:prognostic subgroups and implications forfurther revision of staging based on analysis of 514stage I cases. Mod Pathol 2011;24:653-664.
11. Russell PA, Wainer Z, Wright GM, et al. Does lungadenocarcinoma subtype predict patient survival?:A clinicopathologic study based on the new InternationalAssociation for the Study of Lung Cancer/American Thoracic Society/European Respiratory Societyinternational multidisciplinary lung adenocarcinomaclassification. J Thorac Oncol 2011;6:1496-1504.
12. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validationof the IASLC/ATS/ERS lung adenocarcinoma classificationfor prognosis and association with EGFR andKRAS gene mutations: analysis of 440 Japanesepatients. J Thorac Oncol 2013;8:52-61.
13. Kadota K, Colovos C, Suzuki K, et al. FDG-PETSUVmax combined with IASLC/ATS/ERS histologicclassification improves the prognostic stratification ofpatients with stage I lung adenocarcinoma. Ann SurgOncol 2012;19:3598-3605.
14. Freier K, Flechtenmacher C, Walch A, et al. DifferentialKIT expression in histological subtypes ofadenoid cystic carcinoma of the salivary gland. OralOncol 2005;41:934-939.
15. Jaso J, Malhotra R. Adenoid cystic carcinoma. ArchPathol Lab Med 2011;135:511-515.
16. Aubry M-C, Heinrich MC, Molina J, et al. Primaryadenoid cystic carcinoma of the lung. Cancer2007;110:2507-2510.
17. Molina JR, Aubry MC, Lewis JE, et al. Primary salivarygland-type lung cancer. Cancer 2007;110:2253-2259.
18. Azoulay S, Lae M, Freneaux P, et al. KIT is highlyexpressed in adenoid cystic carcinoma of the breast, abasal-like carcinoma associated with a favorableoutcome. Mod Pathol 2005;18:1623-1631.
19. Rabban JT, Swain RS, Zaloudek CJ, et al. Immunophenotypicoverlap between adenoid cystic carcinoma andcollagenous spherulosis of the breast: potential diagnosticpitfalls using myoepithelial markers. ModPathol 2006;19:1351-1357.
20. Jokoji R, Yamasaki T, Minami S, et al. Combination ofmorphological feature analysis and immunohistochemistryis useful for screening of EML4-ALK-positive lungadenocarcinoma. J Clin Pathol 2010;63:1066-1070.
21. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensivehistologic analysis of ALK-rearranged lung carcinomas.Am J Surg Pathol 2011;35:1226-1234.
22. Rubin MA, de La Taille A, Bagiella E, et al. Cribriformcarcinoma of the prostate and cribriform prostaticintraepithelial neoplasia: incidence and clinical implications.Am J Surg Pathol 1998;22:840-848.
23. Epstein JI. An update of the Gleason grading system.J Urol 2010;183:433-440.
24. Iczkowski KA, Torkko KC, Kotnis GR, et al. Digitalquantification of five high-grade prostate cancerpatterns, including the cribriform pattern, and theirassociation with adverse outcome. Am J Clin Pathol,2011,136,98-107.
25. Egashira Y, Yoshida T, Hirata I, et al. Analysis ofpathological risk factors for lymph node metastasis ofsubmucosal invasive colon cancer. Mod Pathol2004;17:503-511.
26. Ellis IO, Galea M, Broughton N, et al. Pathologicalprognostic factors in breast cancer. II. Histologicaltype. Relationship with survival in a large study withlong-term follow-up. Histopathology 1992;20:479-489.
27. Colleoni M, Rotmensz N, Maisonneuve P, et al.Outcome of special types of luminal breast cancer.Ann Oncol 2012;23:1428-1436.
28. Edge SB, Byrd DR, Compton CC, et al. American JointCommittee on Cancer Cancer Staging Manual, 7th edn.Springer: New York, NY, USA; 2009, pp 253-270.
29. Kadota K, Suzuki K, Kachala SS, et al. A gradingsystem combining architectural features and mitoticcount predicts recurrence in stage I lung adenocarcinoma.Mod Pathol 2012;25:1117-1127.
30. Suzuki K, Kadota K, Sima CS, et al. Clinical impact ofimmune microenvironment in stage I lung adenocarcinoma:tumor interleukin-12 receptor beta2 (IL-12Rbeta2),IL-7R, and stromal FoxP3/CD3 ratio areindependent predictors of recurrence. J Clin Oncol2013;31:490-498.
31. Thomas JS, Kerr GR, Jack WJ, et al. Histologicalgrading of invasive breast carcinoma-a simplificationof existing methods in a large conservation serieswith long-term follow-up. Histopathology 2009;55:724-731.
32. Asamura H, Ando M, Matsuno Y, et al. Histopathologicprognostic factors in resected adenocarcinomas: isnuclear DNA content prognostic? Chest 1999;115:1018-1024.
33. Kadota K, Suzuki K, Colovos C, et al. A nuclear gradingsystem is a strong predictor of survival in epitheloiddiffuse malignant pleural mesothelioma. Mod Pathol2012;25:260-271.
34. Travis WD, RushW, Flieder DB, et al. Survival analysisof 200 pulmonary neuroendocrine tumors withclarification of criteria for atypical carcinoid and itsseparation from typical carcinoid. Am J Surg Pathol1998;22:934-944.
35. Baak JP. Mitosis counting in tumors. Hum Pathol1990;21:683-685.
36. Kadota K, Nitadori J, Sarkaria IS, et al. Thyroidtranscription factor-1 expression is an independentpredictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients withstage I lung adenocarcinoma. Cancer 2013;119:931-938.
37. Paik JH, Choi C-M, Kim H, et al. Clinicopathologicimplication of ALK rearrangement in surgicallyresected lung cancer: a proposal of diagnostic algorithmfor ALK-rearranged adenocarcinoma. Lung Cancer2012;76:403-409.
38. Paik JH, Choe G, Kim H, et al. Screening of anaplasticlymphoma kinase rearrangement by immunohistochemistryin non-small cell lung cancer: correlationwith fluorescence in situ hybridization. J Thorac Oncol2011;6:466-472.
39. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation ofIHC and FISH for ALK gene rearrangement in nonsmallcell lung carcinoma: IHC score algorithm forFISH. J Thorac Oncol 2011;6:459-46540.
40. Pan Q, Pao W, Ladanyi M. Rapid polymerase chainreaction-based detection of epidermal growth factorreceptor gene mutations in lung adenocarcinomas.J Mol Diagn 2005;7:396-403.
41. Pao W, Wang TY, Riely GJ, et al. KRAS mutations andprimary resistance of lung adenocarcinomas to gefitinibor erlotinib. PLoS Med 2005;2:e17.
42. Nishino M, Klepeis VE, Yeap BY, et al. Histologic andcytomorphologic features of ALK-rearranged lungadenocarcinomas. Mod Pathol 2012;25:1462-1472.
43. McLeer-Florin A, Moro-Sibilot D, Melis A, et al.Dual IHC and FISH testing for ALK gene rearrangementin lung adenocarcinomas in a routine practice: aFrench study. J Thorac Oncol 2012;7:348-354.